Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving PetMed Express, Inc. and its officers or directors [1] Group 1: Company Actions - On June 10, 2025, PetMed announced a delay in releasing its fourth quarter and fiscal year 2025 earnings due to the need for additional time to complete the year-end audit process [3] - Following the announcement of the delay, PetMed's stock price dropped by $0.47 per share, representing an 11.22% decline, closing at $3.72 per share on June 11, 2025 [3] Group 2: Legal Context - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of fighting for victims of securities fraud and corporate misconduct [4]
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PetMed Express, Inc. - PETS